INTRODUCTION
============

Huggins and Hodges \[[@B1]\] introduced androgen deprivation therapy (ADT) for prostate cancer based on the concept of androgen sensitivity. Its benefit as adjuvant therapy is well established, particularly in intermediate or high-risk patients \[[@B2],[@B3],[@B4],[@B5],[@B6]\]. ADT is also a treatment option with survival benefits for metastatic or incurable advanced prostate cancer. However, ADT is not definitive therapy for metastatic prostate cancer; therefore, the disease will progress and ultimately become castration resistant \[[@B7]\].

Despite a lack of data on primary androgen deprivation therapy (PADT), the number of patients receiving PADT as an alternative to other local therapies is increasing. In a 1999 to 2001 survey, PADT was the second most common treatment for localized prostate cancer \[[@B8]\]. If patients do not want definite therapy for prostate cancer or are a high operative risk due to advanced age or medical comorbidities, PADT is often used instead of definite local therapy \[[@B9],[@B10]\]. Therefore, this retrospective study examined the clinical characteristics of patients undergoing PADT for prostate cancer and evaluated the factors affecting disease progression while receiving this treatment.

MATERIALS AND METHODS
=====================

1. Study population
-------------------

The study enrolled all prostate cancer patients registered at five centers in Korea (three in Busan, one in Ulsan, and one in Seoul) who had undergone PADT for prostate cancer between 2000 and 2010. In all, 240 patients were studied. The collection and analysis of data were approved by the Institutional Review Board of each medical center. We retrospectively reviewed the PADT therapy data in terms of a comparison with prostate-specific antigen (PSA) progression. The patients were classified into three groups based on clinical stage: localized, locally advanced, and metastatic prostate cancer. Localized prostate cancer was defined as stage T1 to 2 without nodal invasion or distant metastasis. Locally advanced prostate cancer was defined as stage T3a, T3b, or T4 or N1 associated with any T stage if combined with an absence of distant metastasis. Metastatic prostate cancer was defined by the existence of any distant metastasis. All tumor stages were based on the tumor-node-metastasis (TNM) staging system \[[@B10]\].

The PSA nadir was defined as the lowest PSA level while on PADT. PSA progression was defined as three consecutive PSA increases from the PSA nadir while on PADT \[[@B9]\].

2. Statistical analysis
-----------------------

The analysis was performed using IBM SPSS Statistics version 20 (IBM Co., Armonk, NY, USA). The demographic, clinical, and pathological characteristics of the subjects were examined. The data were summarized using the median and range values. Clinical variables-such as age, body mass index (BMI), prostate size, and PSA levels- were compared among the groups by using analysis of variance. Categorical variables were compared using the chi-squared test and Fisher\'s exact test.

PSA progression was analyzed using a Kaplan-Meier curve, and a Cox regression model was used to identify predictors of PSA progression by univariate and multivariate analyses. A p value of \<0.05 was considered to indicate statistical significance.

RESULTS
=======

The clinical and pathological characteristics of the PADT patients are summarized in [Table 1](#T1){ref-type="table"}. The median follow-up on PADT was 24 months (range: 3\~115) months. The median patient age was 73.0 years, and the median pretreatment PSA level was 47.0 ng/mL. Of the patients, 91.7% were treated with combined androgen blockade and 8.3% with monotherapy.

Differences among the three groups according to clinical stage are shown in [Table 2](#T2){ref-type="table"}. Of the patients, 33.3% had localized, 22.5% had locally advanced, and 44.2% had metastatic prostate cancer. There were no significant differences in follow-up period or age among the groups. The patients with metastatic prostate cancer had the lowest BMI (22.5 kg/m^2^). The PSA levels at diagnosis were 14.9, 27.8, and 103.9 ng/mL in the localized, locally advanced, and metastatic groups. Of the patients with locally advanced prostate cancer, 48.1% had lymph node metastasis and 87.1% were at a more advanced stage than T3.

Clinical factors related to PSA progression were identified using Cox regression ([Table 3](#T3){ref-type="table"}). In the multivariate analysis, PSA nadir and stage significantly affected PSA progression during PADT, with hazard ratios of 4.26 and 2.60 (p\<0.001), respectively.

[Fig. 1](#F1){ref-type="fig"} shows the Kaplan-Meier analysis of the PSA progression- free survival rate after 3 years according to stage; the estimated values were 56.1%, 43.4%, and 16.1% (p=0.001), in the localized, locally advanced, and metastatic groups, respectively. The estimated PSA recurrence- free median survival durations in the respective groups were 57, 24, and 12 months.

There was a significant difference in the survival rate between a PSA nadir of ≤0.2 and \>0.2 ng/mL ([Fig. 2A](#F2){ref-type="fig"}). Therefore, we considered a PSA level of 0.2 ng/mL to be the optimal PSA nadir after PADT. Using a PSA nadir of 0.2 ng/mL, we analyzed the progression-free survival rate in each stage. For the localized stage, the survival rate for a PSA nadir of ≤0.2 ng/mL was 62.1%, and the estimated median survival duration was 57 months, versus 15.1% and 15 months for a PSA nadir of \>0.2 ng/mL ([Fig. 2B](#F2){ref-type="fig"}). For locally advanced disease, the PSA progression-free survival rate was 49.3% for a PSA nadir of ≤0.2 ng/mL, and the estimated median survival duration was 29 months ([Fig. 2C](#F2){ref-type="fig"}). In the metastatic stage, the PSA progression- free survival rate was 28.9%, and the estimated median survival duration was 19 months ([Fig. 2D](#F2){ref-type="fig"}).

[Fig. 3](#F3){ref-type="fig"} shows differences in the progression-free survival rate according to Gleason score. There were no significant differences in the progression-free survival rate when analyzed using Gleason scores of 6, 7, and 8 to 10 in localized, locally advanced, and metastatic prostate cancer after PADT.

DISCUSSION
==========

No prospective study has compared PADT with control groups (e.g., conservative treatment, surgery, or other local therapy), and bias might affect patient selection. There are also no guidelines for PADT in terms of patient indications, tumor characteristics, life expectancy, starting and stopping times of therapy, and duration of therapy. Therefore, the selection of patients for PADT is important; the tumor characteristics should also be considered. Our study also did not compare the results with the results of any other definitive therapy or active surveillance. However, multicenter data regarding the trends and current state of PADT in Korea might assist clinicians in selecting appropriate PADT therapy.

Although there is insufficient evidence regarding the benefits of PADT in prostate cancer management, several studies have suggested its efficacy or clinical benefits. A retrospective study of the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) data analyzed 993 males treated with PADT \[[@B11]\]. The 5-year disease-specific survival rate was 95.9%, and only 4.1% died from prostate cancer. In addition, 5 years after starting PADT, the treatment was still being applied to 67.3% of the patients. A long-term (20-year) single-center experience with PADT in localized or advanced prostate cancer reported results similar to those of the CaPSURE study \[[@B12]\]. The 5-, 10-, and 15-year disease-specific survival rates were 95.7%, 91.7%, and 84.9%, respectively. They also compared PADT with salvage ADT-no significant differences in disease-specific survival were evident. In a study comparing radical prostatectomy and PADT, the patients who underwent radical prostatectomy had a higher 10-year overall survival due to their longer expected life span (73% vs. 41%) \[[@B13]\]. However, there was no significant difference in the cancer-specific survival rate (86% vs. 78%). Therefore, PADT is an alternative treatment for prostate cancer, particularly for patients with a short expected life span with localized or locally advanced prostate cancer.

Contrasting these favorable results, a study of The Surveillance, Epidemiology, and End Result (SEER) program of national cancer institute data of patients \>65 years of age suggested that a careful approach to PADT is warranted. Early PADT for localized prostate cancer, particularly low-risk cancer, is associated with an increased frequency of chemotherapy use \[[@B14]\]. This result was based on the molecular mechanism associated with an androgen receptor \[[@B15],[@B16],[@B17],[@B18],[@B19]\]. Lu-Yao et al \[[@B20]\] also investigated survival after PADT in localized prostate cancer and found that PADT reduced the 10-year disease-specific survival rate with a hazard ratio of 1.17 and was associated with no benefit in the 10-year overall survival rate compared with conservative treatment. They concluded that elderly patients with T1 to 2 prostate cancer derived no clinical benefit from PADT. However, these results did not show the uselessness of PADT but rather that the early start of PADT had no benefit as compared to conservative treatment in old-age patients.

Compared with the 75% 5-year progression-free survival rate of the Portland Veterans Affairs Medical Center, the survival rate for localized and locally advanced prostate cancer in our study (56.1% and 43.4%, respectively) was relatively low \[[@B9]\]. In 2009, Kim et al \[[@B21]\] reported that the 5-year progression-free survival in Korean patients was 73.6%. The most important reason for the lower progression- free survival rate in our study is the difference in the definition of progression. We defined progression after PADT as any increase in PSA after reaching the PSA nadir, while most studies used a definitive cut-off value for PSA, even if the patient\'s PSA nadir was lower than the cut-off value, or defined PSA progression as three consecutive PSA increases. For example, if the PSA nadir after PADT is 0.1 ng/mL but the PSA continues to increase, the patient is not considered to be experiencing progression. Only when the PSA level reaches a value above the cut-off, e.g., 4 ng/mL, is the patient classified as experiencing progression. Therefore, we detected patients showing PSA progression after PADT earlier than in other studies. We defined PSA progression as any PSA elevation during PADT to determine when the change in PSA occurs during PADT and to determine the optimal PSA nadir in patients with PADT.

Another possible reason for the difference as compared to other studies is the patient distribution. The median PSA in our series was 47.0 ng/mL, which was considerably higher than the 13.8 in Janoff et al \[[@B9]\] and 13.52 in Kim et al \[[@B21]\]. More advanced prostate cancer patients were selected for PADT in our series; this might have caused the differences in the survival rate. In addition, increasing use of surgery and radiation therapy might contribute to the low progression-free survival rate in PADT patients. Similarly, results of a study of the Japanese population showed a tendency for the survival with PADT to decrease from 50% to 40%, comparing 2004 to 2006 vs. 2007 to 2009 \[[@B22]\]. Despite these differences, the Asian consensus statement on PADT recommends using PADT even in the early stage \[[@B23]\].

The clinical stage and PSA nadir after PADT were independent predictors of PSA progression in our study. A PSA nadir greater than 0.2 ng/mL predicted a poor response to PADT for all clinical stages. In contrast, age at diagnosis and Gleason score were not associated with PSA progression. Young patients or those with a longer expected life span tend to have more aggressive prostate cancer; therefore, cancer progression in such individuals is more frequent than in elderly patients \[[@B24],[@B25]\]. However, we found that age was not associated with cancer progression among the patients who underwent PADT, perhaps because of the relatively young age used as a cut-off in this study. The Gleason score also showed no significant relationship with PSA progression after PADT for any stage, with p values of 0.918, 0.208, and 0.847 for localized, locally advanced, and metastatic cancer, respectively. Therefore, contrary to expectations, cell differentiation in prostate cancer did not influence PSA progression after PADT in our study.

A major limitation of this study was the lack of a control group, such as a group of patients who underwent other local definitive therapy (surgery or radiation) or active surveillance. Another limitation was that no analysis of overall survival or cancer-specific survival was performed. Therefore, the efficacy and clinical benefits of PADT could not be estimated. However, we report the characteristics and trends of PADT in Korea through multicenter experiences for the first time ever, and expect this study to be a foundation for another prospective study on PADT.

CONCLUSIONS
===========

In spite of some limitations and debates, PADT may be another option for prostate cancer control from the perspective of a less invasive treatment. However, the indications for PADT must be considered carefully, including patient age, cancer stage, tumor characteristics, treatment- related comorbidities, and socioeconomic status. Further, the observation for reaching the PSA nadir should be required for a response expectation. After more longterm follow-up data have been obtained, a large-scale comparison study is required to assess the efficacy of PADT.
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###### 

Characteristics of the patients treated with primary androgen-deprivation therapy
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Values are presented as median (range) or number (%).

PSA: prostate-specific antigen, BMI: body mass index, LHRH: luteinizing hormone-releasing hormone.

^a^All tumor stages were based on the tumor-node-metastasis (TNM) staging system.

###### 

Comparison of the patients treated with primary androgen-deprivation therapy according to prostate cancer stage

![](wjmh-32-159-i002)

Values are presented as median (range) or number (%).

BMI: body mass index, PSA: prostate-specific antigen.

^a^All tumor stages were based on the tumor-node-metastasis (TNM) staging system.
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Clinical factors predictive of PSA progression based on a Cox regression analysis
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PSA: prostate-specific antigen, CI: confidence interval.
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